Update on anti-tumor necrosis factor agents in Crohn disease (original) (raw)
Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report
Dario Sorrentino
Inflammatory Bowel Diseases, 2012
View PDFchevron_right
Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs Disease
Maria Etchevers
Drugs, 2010
View PDFchevron_right
Crohn's disease: future anti–tumor necrosis factor therapies beyond infliximab
Joshua Korzenik
Gastroenterology Clinics of North America, 2004
View PDFchevron_right
Do Not Assume Symptoms Indicate Failure of Anti–Tumor Necrosis Factor Therapy in Crohn's Disease
David Bruining
Clinical Gastroenterology and Hepatology, 2011
View PDFchevron_right
Infliximab in the treatment of Crohn's disease
silvio laureti
Therapeutics and Clinical Risk Management, 2007
View PDFchevron_right
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
Andrzej Pilc
View PDFchevron_right
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
J. Ceuppens, K. Geboes
Alimentary Pharmacology and Therapeutics, 2001
View PDFchevron_right
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
Gerassimos Mantzaris
Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology
View PDFchevron_right
Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Brigitte Sola
Recent Patents on Inflammation & Allergy Drug Discovery, 2007
View PDFchevron_right
CDP571, a Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody in Pediatric Crohn’s Disease
Jatin Patel
Inflammatory Bowel Diseases, 2004
View PDFchevron_right
Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
Govind Makharia
Scientific Reports, 2021
View PDFchevron_right
Crohn's disease: beyond antagonists of tumour necrosis factor
Jean-frédéric Colombel, Laurent Peyrin-biroulet
The Lancet, 2008
View PDFchevron_right
Crohn’s Disease Biologic Therapies Advances: A current review
Jorge Balteiro
2017
View PDFchevron_right
Infliximab in treatment of Crohn's disease: the Milan experience
Sandro Ardizzone
Digestive and Liver Disease, 2002
View PDFchevron_right
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
Susi Ati
The American journal of gastroenterology, 2005
View PDFchevron_right
AntiTumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohn's Disease
Christian D Muller
Recent Patents on Inflammation & Allergy Drug Discovery, 2007
View PDFchevron_right
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
William Sandborn
The American journal …, 2001
View PDFchevron_right
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease
Usha Chauhan
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2004
View PDFchevron_right
Early treatment with anti‐tumor necrosis factor agents improves long‐term effectiveness in symptomatic stricturing Crohn’s disease
Marta Piqueras
United European Gastroenterology Journal
View PDFchevron_right
Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study
Gillian Mahy
Alimentary pharmacology & therapeutics, 2017
View PDFchevron_right
The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
Jean-frédéric Colombel
Gastroenterology, 2004
View PDFchevron_right
Maintenance treatment with infliximab for the management of Crohn’s disease in adults
Michele Cicala
Biologics: Targets & Therapy, 2009
View PDFchevron_right
The efficacy, tolerability and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn’s disease
Grażyna Rydzewska
Polish Archives of Internal Medicine
View PDFchevron_right
Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials
Shekoufeh Nikfar
Biomedecine & Pharmacotherapy, 2007
View PDFchevron_right
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease
Guy Aumais
Canadian Journal of Gastroenterology, 2009
View PDFchevron_right
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
William Sandborn
The American journal …, 2004
View PDFchevron_right
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
Bruce Salzberg MD, FACG
Inflammatory Bowel Diseases, 2018
View PDFchevron_right
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial
Guillermo Bastida
Alimentary Pharmacology & Therapeutics, 2007
View PDFchevron_right